NCI Cancer Genome Atlas Program Tissue Purchase

This vehicle is closed to new orders and no longer active for business development pursuit. The National Cancer Institute (NCI), under the Department of Health and Human Services National Institutes of Health, established this Master IDIQ for clinically annotated biospecimens supporting the Cancer Genome Atlas (TCGA) program on January 25, 2010, with a last date to order of July 31, 2015—more than a decade ago. All 69 delivery orders were awarded in 2010, with ordering activity concentrated between January and September 2010. The combined potential value of $12.5 million has already been fully obligated, with $12.6 million actually spent against the vehicle.

The scope is narrowly defined: procurement of tissue samples and clinical data for specific cancer types including glioblastoma multiforme, lung squamous cell carcinoma, breast ductal and lobular carcinoma, colon adenocarcinoma, lung adenocarcinoma, stomach adenocarcinoma, and other cancer types. All task orders funded Recovery Act (ARRA) programs under TAS 75 0850 or subordinate TAS codes. Pricing across all orders is firm fixed price.

Competition is fragmented across 40 distinct prime contractors. The top five primes by order count hold only 35 percent of awards: Sloan-Kettering Institute For Cancer Research (8 orders, $1.4 million), University Of Pittsburgh (6 orders, $1.2 million), The University Of Texas M.D. Anderson Cancer Center (4 orders, $1.3 million), Indivumed, Inc. (3 orders, $2.3 million), and The Johns Hopkins University (3 orders, $344 thousand). By combined potential value, Indivumed, Inc. leads at $2.3 million across three orders. The top five contractors collectively represent 54 percent of the vehicle's potential value. All 69 orders funded a single customer agency, the National Cancer Institute.

Set-aside distribution shows 96 percent of orders (66 awards) carried no set-aside, with only 4 percent (3 orders) designated Total Small Business. Individual task-order values range from under $3,000 to $1.34 million, with typical orders in the $100,000 to $600,000 range. All orders carried performance periods through 2013–2015, reflecting the vehicle's 2010 origination and American Recovery and Reinvestment Act funding cycle.

The National Cancer Institute (NCI) is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality well annotated biospecimens suitable for use in genomic studies. The NCI's overarching goal with such programs is to improve the ability to diagnose, treat, and prevent cancer. The Cancer Genome Atlas (TCGA), one such program, is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies. As such, the NCI has awarded a Master IDIQ for clinically annotated biospecimens to TCGA for the following cancer types: Glioblastoma multiforme, Lung squamous cell carcinoma, Breast ductal carcinoma, Colon adenocarcinoma, Breast lobular carcinoma, Lung Adenocarcinoma , Stomach adenocarcinoma, and Other Cancer Types.